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The wound healing potency of an aqueous extract of placenta can be evaluated through the presence
of numerous regulatory components. The presence of glycans was detected by thin layer chromatog-
raphy and ﬂuorophore-assisted carbohydrate electrophoresis. Mass spectrometric analysis revealed
the existence of multiple fragments of immunoglobulin G (IgG). IgG was present in the extract at a
concentration of 25.2 ± 3.97 lg/ml. IgG possesses anti-complementary activity by diverting the
complement activation from target surface. Thus, effect of placental IgG on complement–bacteria
interaction was investigated through classical and alternative pathway and the preparation was
ascertained to be safe with respect to their interference in the process of bacterial opsonization.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Characterization of this placental extract lead to the identiﬁcationImmunoregulatory effects of human placental extract along
with wound healing ability, hormonal regulation, prevention of
recurring respiratory infections, asthmatic bronchitis, etc. are
clinically well established [1–7]. Consistent maintenance of fetal-
maternal nutrient exchange through placenta endures the organ
to have remarkable therapeutic potential. This is exhibited through
multiple independent mechanisms in order to exhibit the cumula-
tive effect. An aqueous extract of human placenta, the preparation
of which has been elaborated in the text, plays an imperative role
in various stages of healing. Studies have demonstrated its role in
modulation of cytokine induction during different phases of heal-
ing, effective stimulation of collagen synthesis during regeneration
and epithelialisation and placental growth factor (PIGF) as an
accelerator of granulation tissue maturation [8–10].of numerous biological regulators such as growth factors, recep-
tors, glycosaminoglycans and PDRNs [11–19]. These ﬁndings indi-
cate that placental extract plays a deﬁnitive role in wound repair
through multiple regulatory mechanisms.
The role played by complex carbohydrates in wound repair is an
active topic of investigation since the carbohydrate moieties of gly-
coconjugates are often important as recognition determinants in
cellular interactions, modulation of immunogenicity etc. [20,21]. A
previous study showed that in a Pax6+/ mouse model of Aniridia-
related keratopathy, mutations in glycoconjugate composition of
the cell surfacemight lead to an abnormal cellularmigration pheno-
type [22]. This could cause impaired re-epithelialisation which in
turn could elevate risk of infection, inﬂammation and undermine
normal stromal remodeling. Another study suggested that cell sur-
face proteins which are N-glycosylated with terminal fucosylation
mediatedwound closure of airway epithelialmonolayer by promot-
ing cellular adhesion and migration [23]. These observations have
important implications in understanding the critical role played by
the glycans moieties in augmenting wound repair.
Injury to the skin is equivalent to an immunological crisis since
the sub-epidermal exposed tissue is vulnerable to bacterial colo-
nization [24–28]. The innate immune system, which is composed
of phagocytes and the complement system, provides the primary
line of defense against invading pathogens [29]. The complement
system which is composed of more than 50 plasma and membrane
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immune responses [30–32]. It generates a ﬂux of active signaling
molecules that includes C1q, C3, C4 and C5, which help to orches-
trate the recruitment of phagocytes from blood. The complement
activation proceeds primarily through two pathways: classical
and alternative. Another pathway involved in the complement
activation is the Mannan-Binding Lectin (MBL) pathway. MBL trig-
gers complement similar to C1q. All these pathways are activated
by different molecules but in the end, they all converge to generate
the same set of effector molecules [33]. The inﬂammatory response
promotes the recruitment of neutrophils which cause the debride-
ment of necrotic and apoptotic cells and eliminate infectious
agents from the wound bed. Role of complement in wound healing
has been exempliﬁed by the involvement of C3a and C5a in pro-
moting liver regeneration [34]. C1q, another member of the com-
plement cascade, possesses proangiogenic activity along with the
increase in tissue strength, inﬂammation, ﬁbroblast migration
and collagen deposition post application of C3 on wounded surface
[35–37]. In wound physiology, bacteria compete for the nutrients
in the wound milieu and cause signiﬁcant destruction to the
wound matrix [38]. Wound debridement is an effective method
to physically remove the dead, devitalized tissue and reduce the
bacterial bioburden. On the other hand, the complement system,
based on its ability to interact with bacteria, provides an element
of natural immunity. In order to evaluate the effect of promoter/
inhibitor molecules on the complement mediated opsonization of
bacteria, pseudomonas aeruginosa was used as the chosen strain
because of its common availability in infected wound matrix. It
is an opportunistic gram negative pathogen which causes serious
infections in patients with severe burns, wounds injuries [39,40].
This studywas initiated to study the role of glycoconjugates pre-
sent in the placental extract in wound healing. Multiple chromato-
graphic and biophysical evidences indicated the presence of IgG as a
major constituent of glycoprotein content in human placental
extract. IgG is known to be a preferential acceptor of activated C3
andmight interfere in the process of opsonization of bacteria inside
the wound milieu [41,42]. Thus, effect of placental IgG on comple-
ment-bacteria interaction was investigated, through classical and
alternate pathways, to elucidate its role in complement regulation.2. Experimental procedures
2.1. Reagents
Fine chemicals were obtained as follows: Glucose, ammonium
molybdate, sodium dihydrogen arsenate, sodium potassium tar-
trate, ATP, NAD+, hexokinase, G6PDH, copper sulphate, dipheny-
lamine, aniline, ovalbumin, Concanavalin A, CNBr activated
Sepharose 4B, methyl-a-D-mannopyranoside, PNGase F from
Elizabethkingia miricola, sodium cyanoborohydride, reference
human IgG, subtilisin, protein-A conjugated alkaline phosphatase,
protein-A agarose, BSA, protein A-alkaline phosphatase, p-nitro-
phenyl phosphate, EDTA, EGTA from Sigma, USA; P. aeruginosa
(ATCC 51679), BHI, phosphoric acid, agar from Himedia; C18 zip-
tip, silica gel TLC plates from Merck, Germany; periodic acid, acidic
fuschin sulfate, sodium metabisulﬁte from Pierce, USA; ANTS from
Invitrogen; nitrocellulose membrane, BCIP, NBT from Promega;
veronal buffer saline from Lonza. Other reagents were of analytical
grade and purchased locally.
2.2. Placental extract
The drug house M/s Albert David Ltd., Kolkata, India supplied
aqueous extract of human placenta that is sold as a licensed drug
under the trade name ‘Placentrex’. Preparation of the extractholding the conﬁdentiality of the manufacturer’s proprietary terms
has been described [11]. In short, the extract is prepared from fresh
term pooled placentae using single hot (90 C) and cold (6 C)
water extractions followed by sterilization under saturated steam
pressure of 15 psi at 120 C for 40 min. It is routinely tested for
HIV antibody and Hepatitis B surface antigen. It contains 1.5% ben-
zyl alcohol (v/v) as preservative which does not interfere with the
experiments presented here. Collection and handling of the pla-
centa and manufacturing of the drug were done under the export
license of the drug controlling authority of India.
2.3. Analysis of free/bound carbohydrates
2.3.1. Nelson-Somogyi method for reducing sugars
To 0.5 ml of glucose solution (0.0125–0.150 mM) or test sam-
ples, 0.5 ml of Somogyi’s alkaline copper tartrate reagent was
added and kept in a boiling water bath for 10 min. The tubes were
cooled to room temperature and 0.5 ml of Nelson’s arsenomolybdic
reagent was added. The tubes were incubated at 25 C for 10 min
and the A620 nm was read. Somogyi’s and Nelson’s reagents were
prepared after [43]. Colorimetric estimation of molybdenum blue
at 620 nm generated a standard curve of glucose showing linear
dependence between absorbance and concentration (R2 = 0.996,
where R2 is the regression coefﬁcient).
2.3.2. Coupled enzyme assay for glucose
The test sample was added to 0.1 M Tris–HCl, pH 7.5 containing
2.1 mM MgCl2, 1 mM ATP and 1 unit/ml of hexokinase to a ﬁnal
volume of 1 ml and incubated at 25 C for 30 min. Then 1.5 mM
NAD+ and 1 unit/ml of glucose-6-phosphate dehydrogenase was
added and again incubated for 30 min followed by measuring
NADH production at 340 nm [44].
2.3.3. Detection of glycoconjugates by TLC
Glucose and galactose (5 ll, 10 mg/ml) and placental extract
(5 ll, 100) were loaded on a silica gel TLC plate (E Merck,
Germany). Chromatograms were developed with the solvent sys-
tem chloroform: acetic acid: water (12:7.5:1.5). Diphenylamine-
aniline-phosphoric acid spray reagent was used in the detection
of glycoconjugates after heating at 105 C for 2 h [45].
2.3.4. Fluorophore assisted carbohydrate electrophoresis (FACE)
The oligosaccharides present in placental extract were analyzed
using FACE [46,47]. Firstly, the placental extract was deglycosy-
lated using PNGase F (peptide-N-glycosidase F from E. miricola).
Brieﬂy, the extract was dissolved in 50 mM Na-phosphate, pH 7.5
containing 0.005 ml of denaturation solution (0.2% SDS with
0.1 M b-mercaptoethanol) and boiled at 100 C for 10 min. The
solution was cooled and 10 ll (50 units/ml) of PNGase F was added
to the reaction mixture. The solution was incubated at 37 C for
3 h. The released oligosaccharides were dried and labeled by add-
ing 5 ll of 0.2 M ANTS in acetic acid/water (3:17, v/v) and 5 ll of
1 M Na-cyanoborohydride in DMSO. The mixture was incubated
at 37 C for 15 h. Oligosaccharides labeled with ANTS were sub-
jected to 32% PAGE. The stacking gel was 8% acrylamide/0.6%
bisacrylamide. The running buffer was 0.025 M Tris/ 0.192 M
Glycine, pH 8.4 and the electrophoresis was run at a constant cur-
rent of 15 mA for 2 h.
2.3.5. Quantiﬁcation of glycoprotein
Glycoprotein content of the extract was estimated by Schiff-peri-
odic acid staining procedure using ovalbumin as reference.
Ovalbumin (10–200 lg) and placental extract (50 ll; 100 conc.)
were electrophoresed in15%/20% SDS–PAGE respectively and stained
usingGelCodeGlycoproteinStainingKit (Pierce) [19]. ImageJ densit-
ometric analysis was performed to quantify glycoprotein staining. It
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tration of ovalbumin (10–200 lg/ml; R2 = 0.967).
2.4. Puriﬁcation and identiﬁcation of glycoproteins in placental extract
2.4.1. Concanavalin A-Sepharose afﬁnity chromatography
Glycoproteins of placental extract were puriﬁed by
Concanavalin A- Sepharose afﬁnity chromatography [19]. Further,
0.05 M b-mercaptoethanol and 26 N sulfuric acid were added to
each fraction and absorbance was measured at 413 nm to deter-
mine the presence of glycans.
2.4.2. Reverse phase HPLC
The released glycoproteins/peptides were separated using RP-
Nova-Pak C18 HPLC column (Waters, 3.9  150 mm, 4 lm). The
unbound components were washed with water while the bound
fractions were eluted by a linear gradient of 0–80% acetonitrile
for 60 min. Elution was followed at 220/280 nm.
2.4.3. MALDI ToF MS/MS
The fractions from RP-HPLC were deglycosylated using PNGase
F as mentioned above. The reaction mixture was applied to a
Concanavalin A Sepharose spin column at 1500 rpm for 5 min to
remove the released oligosaccharides. To each sample were added
15 ll of 50 mMNa-bicarbonate and 1.5 ll of 100 mMDTT [48]. The
samples were incubated at 60 C for 1 h. Then 3 ll of 100 mM
iodoacetamide was added and incubated in the dark for 30 min.
Post alkylation, the peptides were digested using chymotrypsin
(2 lg) for 16 h at 37 C. Digested peptides were desalted using aFig. 1. (A) TLC proﬁle of glycans. Lane a: glucose; Lane b: galactose and Lane c: placental e
acid stain after 20% SDS–PAGE. Lane a: 25 ll and Lane b: 50 ll of placental extract. (D) Sc
75; 5, 100; 6, 200 lg of ovalbumin. (E) Densitometric scan of (D) by Image J software t
amount of protein is demonstrated (R2 = 0.967).C18 zip-tip (0.2 ll bed volume), eluted with 50% acetonitrile/0.1%
triﬂuoroacetic acid and applied to the MALDI plate along with
the matrix a-cyano-4-hydroxycinnamic acid (CHCA) at a ratio of
1:1 (v/v, 0.45 ll each). MS analysis were performed using a 4700
MALDI ToF (Applied Biosystems) operated in reﬂectron mode.
The MS/MS of the most intense chymotryptic peptide mass ion
were searched against Swissprot and NCBI database using Mascot
(Matrix Science Ltd., London, U.K; http://www.matrixscience.
com/) search program with ﬁxed and variable modiﬁcations; car-
bamidomethyl and oxidation respectively.
2.5. Identiﬁcation and Puriﬁcation of IgG
2.5.1. Dot-Blot
Reference IgG, placental extract and subtilisin (negative control)
were spotted on a nitrocellulose membrane and dried completely
and incubated with PBS containing 0.1% Tween 20 and 1% BSA at
4 C for 15 h. The strip was washed thrice with PBS containing
0.1% Tween 20 for 10 min each. The strip was then incubated with
Protein A-conjugated alkaline phosphatase (1:500) for 2 h. Strip
was again washed and presence of IgG was conﬁrmed on the basis
of color development using BCIP-NBT in 0.1 M Tris–HCl, pH 8.8.
Subtilisin is a protein of bacterial origin thus, eliminating the pos-
sibility of cross reaction with proteins of mammalian origin.
2.5.2. Protein A-agarose afﬁnity chromatography
A 2 ml Protein A-agarose afﬁnity column was prepared and
equilibrated with 0.05 mM Na phosphate, pH 8.0. Placental extract
(10 ml; 10 conc.) was loaded in the column and 2 ml fractionsxtract. (B) FACE proﬁle. Lane a: glucose; Lane b: placental extract. (C) Schiff-periodic
hiff-periodic acid stain after 15% SDS–PAGE of ovalbumin. Lane 1, 10; 2, 25; 3, 50; 4,
o quantify band intensities in terms of area. A linear correlation between area and
Fig. 2. (A) Separation of glycoproteins using Concanavalin A-Sepharose afﬁnity
column. The unbound fraction was eluted using the equilibration buffer followed by
application of a linear gradient of 0–0.5 M methyl a-D-mannoside in the same
buffer to elute glycoproteins. Elution proﬁle at 220 nm (j) has been shown.
Presence of glycans in the fractions was detected at 413 nm by the method of
sulfuric acid-bmercaptoethanol (N). (B) RP-HPLC proﬁle of the pool of glycoproteins
obtained from (A). Fractions 1, 2, 3 and 4 were collected for further analysis.
Chromatograms were recorded at 220 nm (black) and 280 nm (blue).
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same buffer. Bound fractions were eluted using 0.1 M Gly-HCl,
pH 2.2. Eluted fractions were followed at 220 nm.
2.5.3. ELISA
Immunoglobulin G in placental extract was quantiﬁed using
enzyme-linked immunosorbent assays (ELISA) using protein A-al-
kaline phosphatase conjugated. Brieﬂy, both commercial IgG
(0.005–0.1 mg/ml) and placental extract were incubated at 37 C
for 3 h in 96 well microplates. Non-speciﬁc binding sites were
blocked using 1% BSA in PBS pH 7.5 for 2 h. The plates were incu-
bated with 0.05% protein A alkaline phosphatase for 2 h and the
reactions were revealed by incubation with the substrate p-nitro-
phenyl phosphate disodium salt. To obtain the A405 units, plates
were read in an ELISA plate reader. Negative controls included
uncoated, no IgG wells. For determination of IgG concentrations,
absorbance values were plotted against the standard curve
obtained for the dilutions of the standard IgG within a linear range
wherein a linear curve was generated between absorbance and
concentration (R2 = 0.960).
2.6. Analysis of Complement uptake onto bacteria
2.6.1. Complement buffers
Isotonic veronal buffer (VBS) containing 0.5 mM MgCl2,
0.15 mM CaCl2 and 0.1% gelatin in presence (EDTA-GVBS) and
absence (GVBS2+) of 10 mM EDTA were prepared as described in
[49]. Isotonic GVBS2+ containing 8 mM EGTA and 5 mM MgCl2(EGTA-GVBS) for alternative pathway activation assays was pre-
pared after [50].
2.6.2. Bacterial stains
P. aeruginosa (ATCC 51679; SS), a serum-sensitive mucoid strain
was obtained from the sputum of a patient with cystic ﬁbrosis, and
its serum resistant mucoid derivative, SR, was isolated by passage
of SS strain in the presence of increasing concentrations of human
serum [51]. Both strains were maintained on BHI agar at 37 C and
transferred daily. Each strain was grown to mid-log phase (5–6 h)
in BHI broth at 37 C with agitation, harvested by centrifugation at
5000 rpm for 10 min at 4 C, washed twice with VBS and resus-
pended in appropriate buffer.
2.6.3. Pooled normal human serum (PNHS)
Blood was obtained by venipuncture of 5 healthy volunteers
and was allowed to clot at 25 C for 30 min. After centrifugation
at 1000g for 15 min at 4 C, the serum was pooled, ﬁlter sterilized
through a 0.22-lm-pore-size ﬁlter, and stored at 80 C in small
fractions until use. For some experiments, complement in PNHS
was inactivated by heating at 56 C for 30 min. In some assays,
serum was pre-adsorbed with bacteria to be tested, to remove
pre existing reactive antibodies (1 ml of serum adsorbed 4 times
with 108 CFU of mid log phase grown bacteria, on ice for
30 min). The volunteers were non-smokers and were not under
antibiotic medication. Collection of blood was approved by the
institutional human ethics committee.
2.6.4. Complement deposition assay
Mid log phase bacteria were used in all assays. Cells were
washed in assay buffer and resuspended to a ﬁnal concentration
of 1  108 cells/ml. Different concentrations of placental IgG were
added to bacteria before incorporation of a source of complement
(20% PNHS). Reference IgG was used as the control in each
experiment.
Bacteria were incubated with shaking at 37 C for 1 h. At the
end, reaction volume was diluted with EDTA-GVBS and washed
three times with the same buffer. Then, Rb pAb anti-human C3
(1:400) was added and incubated for 60 min at 25 C. Cells were
again washed thrice with EDTA-GVBS and then incubated in goat
anti-rabbit IgG (1:2000) for 1 h in dark. The reactions were
revealed by incubation with the substrate pNPP. Results were
expressed as a percentage of maximal labeled Ab binding to com-
plement components bound to the bacterial surface (human serum
alone). Non-speciﬁc C3 binding was examined by incubating bacte-
ria with buffer alone.
2.6.5. Erythrocytes as a model for evaluation of anti-complementary
activity of placental IgG
Complement binding to sensitized erythrocytes is a well stud-
ied system to evaluate the anti-complementary activity of IgG.
Human erythrocytes were sensitized with rat anti human red
blood cell IgG. Then sensitized erythrocytes were incubated with
various concentrations of placental IgG. Deposition of C3 onto ery-
throcytes was measured using Rb pAb anti-human C3 as described
above.3. Results and discussion
Elucidation of roles played by different components present in
placental extract provides an understanding into its cumulative
effect on tissue repair and healing. Assessment of the role played
by carbohydrates was initiated to investigate the same.
Quantiﬁcation of the reducing sugar content present in human pla-
cental extract was followed using the Nelson–Somogyi method
Fig. 3. (A–D) Mass spectrum of the fractions 1, 2, 3 and 4 of Fig. 2B respectively. Peaks of low intensity and close proximity have been marked by downward arrows.
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9.84 ± 2.42 lg/ml (n = 4). Since glucose is one of the most prevalent
monosaccharide present in human, a coupled enzyme assay was
performed for speciﬁc determination of glucose in placental
extract. The concentration of glucose was estimated to be
9.31 ± 2.82 lg/ml (n = 5). Thus, glucose was a major component
of the reducing sugar content of human placental extract.
Carbohydrates are expected to exist in both free and bound
state in placental extract. Thus, TLC was performed to detect the
presence of glycoconjugates. Application of glucose, galactose
and placental extract (100 conc.) resulted in Rf values 0.67,
0.61, 0.41 respectively (Fig. 1A). Apart from a faint band, no sepa-
ration of components was observed in placental extract. In com-
parison to monosaccharides like glucose and galactose, no spot
for TLC was obtained for placental extract at equivalent migration
point. This indicated that probably free glycans are much less in
amount as compared to conjugates. Subsequently, FACE was done
to detect any separation of components.
After their enzymatic release from glycoproteins, glycans were
reductively aminated and separated using FACE. Glucose was run
as a reference marker of the electrophoretic mobility. In the FACE
proﬁle of placental extract, ANTS derivatives showed a single dif-
fused band with higher electrophoretic mobility than labeled glu-
cose. No separation of components was observed. Thus, TLC
proﬁle and FACE indicated presence of glycans in placental extract
(Fig. 1B and C). Previous reports on Schiff-periodic acid staining
conﬁrmed the presence of glycoconjugates in placental extract
[19]. However, in the absence of any speciﬁc method to quantita-
tively estimate the glycoprotein content of placental extract,
ImageJ densitometric analysis was employed (Fig. 1D).
Glycoprotein content of placental extract was estimated to be
59.77 ± 9.01 lg/ml (n = 5).
The glycopeptide content of the placental extract was isolated
by eluting the bound fraction of Concanavalin A-Sepharose columnusing methyl a-D mannopyranoside as the eluent (Fig. 2A). The
broadness of the unbound fraction was attributed to large volume
of placental extract applied. Presence of glycans in the pooled
bound fraction was determined by speciﬁed protocol (Fig. 2A).
This bound fraction was further applied to Nova-Pak C18 RP-HPLC
column (Fig. 2B). Chromatography proﬁle revealed a pattern with
multiple peaks eluted both in the aqueous as well as organic sol-
vent mediums. Peak fractions with signiﬁcant absorbance were
separately collected and analyzed by MS analysis.
The fractions from RP-HPLC were deglycosylated using PNGase
F, subjected to chymotrypsin digestion and the resulting fragments
were analyzed by MALDI ToF/ToF combined with Mascot search
(Fig. 3, Table 1). The components identiﬁed were lymphocyte
cytosolic protein, trophinin and immunoglobulin G (IgG).
Recurrent occurrence of IgG fragments in the list was, however,
almost always with a low mascot score. This could be attributed
to the impure form of the extract which was used for the analysis.
Various fragments of IgG heavy chain variable region were found
to be repeatedly matching in chromatographic fractions
(Table 1). Reports indicate that the hypervariable (HV) regions
within the variable domain are directly involved in antigen binding
[52]. One such hypervariable fragment (HV 2, residues 48–62,
Accession No. CAB37157) has been indicated on the data list
(Table 1). This region is also referred as the complementarity deter-
mining region (CDR). These observations gave an indication of IgG
being a major component of the glycoprotein content of placental
extract.
Immunoglobulins are glycoproteins which play a critical role in
immune response. However, presence of immunoglobulin in pla-
cental extract has to be attributed to fetal-maternal exchange
which provides passive immunity to the fetus. Literature provides
strong evidences to support the fact that IgG is exclusively trans-
ported across the placenta. Other isotypes are unable to cross the
placental barrier as IgM exist as pentamer; IgA exists as dimer
Table 1
MALDI ToF/ToF analysis and Mascot search of chymotryptic fragments of components separated by RP-HPLC.
Fraction No Protein Accession No. Score Peptide ion m/z Sequence MS/MS derived sequence
1,2,4 Immunoglobulin heavy
chain variable region
(fragment) human
CAB37157 48 1279.6311 71–81 TISRDDSKNML
1376.5643 98–109 CTVGTCISTACF
1562.6437 98–110 CTVGTCISTACFW
1634.8608 48–62 VGRIKNRADGGTIDY
1783.912 67–81 KGRFTISRDDSKNML
1,2,4 Lymphocyte cytosolic
protein 1 (L-plastin)
(fragment) human
Q5TBN4_HUMAN 48 996.536 82–90 KSTDVAKTF
1328.5753 64–74 DQDGRISFDEF
1541.6901 58–71 MATGDLDQDGRISF
1600.6652 1–14 MARGSVSDEEMMEL
1 Immunoglobulin
superfamily member 8
protein (fragment)
human
Q9BTG9_ HUMAN 37 1279.6866 59–69 ARTSTQKHTHL
1376.6917 263–275 RLEAARPGDAGTY
1541.6591 414–426 HCAPSAWVQHADY
1634.8683 217–233 EMAPAGAPGPGRLVAQL
1652.8213 213–229 SVGWEMAPAGAPGPGR
L
3,4 Trophinin-human I38488 45 996.4455 468–477 GGAPSTSLCF
1028.4718 318–327 GGTLSTSVCF
1121.5221 568–581 GGGPGTSTGFGGGL
1154.5688 88–99 SNTASISFGGTL
1165.5483 368–381 GGSPSTSAGFGGAL
1652.7299 705–724 SGGPSTGAGFGGGPNTGAGF
1652.7299 715–734 GGGPNTGAGFGGGPSTSAGF
1783.8496 676–695 SSGPSSIVGFSGGPSTGVGF
3 Ig heavy chain V region
(clone RIV) – human
fragment
PH1660 46 924.4421 79–86 RAEDTAVY
1070.5629 52–60 YVDSVKGRF
1411.7177 61–72 TISRDNSKNTLY
1540.6948 104–118 GMDVWGQGTTVTVSS
3 Ig kappa light chain,
A28 V-segment protein
(fragment) – (human)
CAA31203 42 1070.5001 57–67 SSSGSGTDFIL
1464.7693 68–80 KISRVEAEDVGVY
1627.8325 68–81 KISRVEAEDVGVYY
1708.7959 4–19 LGEPSSISCRSGQSPF
3 Immunoglobulin heavy
chain variable region
precursor (fragment)
human
CAD60375 42 924.4421 97–104 RAEDTAVY
1411.7177 79–90 TISRDNSKNTLY
1540.6948 111–125 GMDVWGQGTTVTVSS
1687.8431 6–21 RGVQCEVQLVESGGGL
3 Immunoglobulin heavy
chain VHDJ region
(fragment) – human
BAC02383 41 936.4632 122–131 GQGTTVTVSS
1154.6165 1–11 QVQLQQSGPGL
1328.6005 87–98 NSVTPEDAAVYY
1540.6948 117–131 GMDVWGQGTTVTVSS
1627.6904 21–36 TCAISGDSVSSDTAAW
3 Ig heavy chain V-III
region (But) – human
A2HUBU 40 924.4421 86–93 RAEDTAVY
1065.4307 28–36 TVSBHSMSW
1427.6761 68–79 TISRDDSRBTVY
1539.7762 68–80 TISRDDSRBTVYL
1540.7603 68–80 TISRDDSRBTVYL
The numbers 1–4 refer to the HPLC fractions described in Fig. 2B.
Fig. 4. (A) Dot blot for the detection of IgG using protein A-conjugated alkaline phosphatase. (1) Human placental extract, (2) reference human IgG as positive control and (3)
subtilisin as negative control. Partial diffusion of the spot in l is a characteristic feature of concentrated placental extract due to ﬂoating of lipid particles. (B) Puriﬁcation of IgG
using protein A-Sepharose afﬁnity column. Bound IgG fraction was eluted using 0.1 M Gly-HCl, pH 3.1 (marked by arrow).
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normally exists in concentration below measurable limit [53–56].
This emphasized the possibility of presence of IgG as the sole
immunoglobulin isotype in placental extract.
This prediction was conﬁrmed by immunoblot analysis. Protein
A is a bacterial protein with the ability to bind immunoglobulins.Thus reactivity between placental extract and protein-A conju-
gated alkaline phosphatase was tested using commercial IgG and
subtilisin as positive and negative control respectively. It was
observed that placental extract developed a deep blue spot along
with commercial IgG. No spot was developed with subtilisin
(Fig. 4A). Next, IgG pool was puriﬁed using protein A-Sepharose
Fig. 5. Effect of placental IgG on C3 binding to P. aeruginosa serum sensitive (A and C) and the derived serum resistant strain (B and D); via the alternative pathway (A and B)
and classical pathway (C and D) using unadsorbed IgG and unadsorbed human serum or extensively adsorbed IgG and human serum. Bacteria were incubated with 20%
human serum in appropriate buffer with varying concentrations of placental IgG or reference human IgG. Bound C3 was detected with an anti C3 antibody. Controls included
cells incubated with buffer alone which is indicative of maximal anti-C3 binding (100%, human serum alone).
Fig. 6. Effect of IgG on C3 binding to sensitized human erythrocytes with rat anti-
human red blood cell IgG. The cells were incubated with varying concentrations of
placental IgG. Bound C3 was detected with an anti C3 antibody. Controls included
cells incubated with buffer alone which is indicative of maximal anti-C3 binding
(100%, human serum alone). Effect of placental IgG and reference IgG have been
presented by ( ) and ( ) respectively.
K. Sharma, D. Bhattacharyya / FEBS Open Bio 5 (2015) 369–377 375afﬁnity chromatography. Bound fraction was eluted using Gly-HCl,
pH 2.4. Puriﬁed IgG was estimated to be 25.2 ± 3.97 lg/ml using
ELISA (Fig 4B).
Pooled IgG preparations are routinely administered to patients
with autoimmune and systemic inﬂammatory diseases. However,reports have indicated the complement regulatory activity of IgG
by acting as a preferential acceptor of activated C3, thus diverting
complement activation from target bacterial surface [57]. In
patients with dermatomyositis, intravenously administered IgG
substantially inhibited activated C3 deposition on target tissue,
thus supporting the anticomplementary potential of IgG [58].
Human placental extract shows signiﬁcant potential as a wound
healer as well as an immune-regulator. Removal of bacterial bur-
den in the wound milieu prevents the progression of an acute
wound into a chronic one. Presence of IgG in placental extract
raised the possibility of its interference in the process of opsoniza-
tion of bacteria. Thus, ability of puriﬁed placental IgG to modify
complement bacteria interaction was investigated through both
alternative as well as classical pathway. P. aeruginosa was the bac-
terial strain of choice due to its persistent occurrence in wound
milieu. Effect of IgG on complement mediated lysis of both serum
sensitive and serum resistant strains was examined to elucidate its
mechanism of action in complement regulation. P. aeruginosa iso-
lated from the sputa of CF patients are generally mucoid, nonty-
pable, deﬁcient in LPS O-side chains, and serum sensitive (SS)
[59]. These were transformed into serum resistant (SR) strains by
repeated passage of increasing concentrations of serum.
Resistance to bactericidal activity of serum is reﬂected in the
increase in lipopolysaccharide O-side chain composition [51].
Both the strains were tested for their susceptibility towards serum
lysis before experimental studies.
Activation of different pathways for bacterial opsonization is
initiated by different mechanisms. Alternative pathway activation
was studied on P. aeruginosa (SS) and the derivative strain (SR) in
376 K. Sharma, D. Bhattacharyya / FEBS Open Bio 5 (2015) 369–377presence of 2.5–51 lg/ml of placental IgG. Within this concentra-
tion range, IgG did not inhibit C3 binding to P. aeruginosa
(Fig. 5A and B). Although GVBS-EGTA was used as the appropriate
buffer to study activation of alternative pathway, adsorption pro-
cedures were performed to eliminate the possibility of comple-
ment activation by antibacterial antibodies. Similar
concentrations of commercial IgG produced comparable results
(Fig. 5A and B). The concentration of commercial IgG used in the
experiments was in accordance with placental IgG, since the
potential of human placental extract towards its effect on innate
immunity was being investigated. Classical pathway activation,
in absence of antibodies, might occur through direct C1q binding.
Thus, serum was heated to 55 C in order to destroy alternative
pathway activity. The serum was further adsorbed with the bacte-
ria to study antibody independent classical pathway activity. No
signiﬁcant modiﬁcation in complement binding to bacterial sur-
face was observed in both serum sensitive and serum resistant
strains (Fig. 5C and D). Sensitized human erythrocytes were used
as a model to complement activation through classical pathway.
It has been reported that C3 binding to sensitized targets might
be observed at higher concentration of IgG [60]. Thus, it was nec-
essary to ascertain whether this concentration range of IgG was
high enough to cause any such effects. However, within the speci-
ﬁed range of 2.5–51 lg/ml of placental IgG, no inhibition of C3
binding was observed (Fig. 6). These results clearly demonstrated
the safety of the human placental extract as an immunoregulatory
agent with respect to interference in the process of normal host
defense.
The placental extract used in this study does not show detect-
able proteolytic activity against azoalbumin and azocasein but
contains collagenolytic activity [18] and ﬁbrinolytic activity (P.
Bhattacharyya, unpublished data). This indicates that the extract
contains proteases of narrow speciﬁcity. Considering the elevated
temperature and pressure used in the manufacture of the extract,
activation of proteases therein and denaturation of such large pro-
teins like IgG (150 kDa), presence of fragmented IgG instead of the
intact molecule is expected. The binding between IgG and C3
occurs through ester and amide bonds. If the IgG fragments are
unable to form these bonds then, inadvertently they will not have
any effect on the complement-bacteria interaction and would thus
ensure the safety of human placental extract towards maintaining
the natural innate immunity of the host.
4. Conclusion
The present study was initiated with the aim to decipher any
speciﬁc role exhibited by glycans in the process of wound healing.
Identiﬁcation of immunoglobulins in placental extract was fol-
lowed by evaluation of their regulatory role in complement path-
way. Using bacterial strains of serum sensitive and resistant
types, it was indicated that placental IgG, apart from its role as
an immunostimulator, does not interfere in the bacterial opsoniza-
tion in the wound milieu. Thus, the administration of placental
extract to a wound patient would not tamper with his/her innate
bacterial defense potential.
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